• Product NameCanertinib dihydrochloride
• Brief DescriptionInhibitors
• Purification99.23%
• Biological ActivityCanertinib Dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Canertinib binds to the intracellular domains of epidermal growth factor receptor tyrosine kinases (ErbB family), irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation. This agent also acts as a radiosensitizing agent and displays synergistic activity with other chemotherapeutic agents.
• Target NameEGFR inhibitor
• CAS No. 289499-45-2
• Calculated MW 558.86
• Formulation C24H27Cl3FN5O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:FC1=C(Cl)C=C(NC2=NC=NC3=CC(OCCCN4CCOCC4)=C(NC(=O)C=C)C=C23)C=C1
  Pathways:Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
  Receptor:EGFR; HER2/ErbB2
  Boling pt:
  Melting pt:
  Solubility:Soluble in DMSO
  Appearance:Faint Yellow Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Smaill JB et al. J Med Chem. 2000; 43(7): 1380-1397.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting